Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
作者信息
Harding M J, Cantwell B M, Milstead R A, Harris A L, Kaye S B
机构信息
Department of Medical Oncology, University of Glasgow, UK.
出版信息
Br J Cancer. 1988 Jun;57(6):628-9. doi: 10.1038/bjc.1988.143.
Abstract
摘要
相似文献
1
Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.胸苷酸合成酶抑制剂CB3717（N10-炔丙基-5,8-二去氮叶酸）用于结直肠癌的II期研究。
Br J Cancer. 1988 Jun;57(6):628-9. doi: 10.1038/bjc.1988.143.
2
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).CB3717（N10-炔丙基-5,8-二去氮叶酸）抑制胸苷酸合成酶并不能增强5-氟尿嘧啶对人类结直肠癌的疗效。
Br J Cancer. 1988 Aug;58(2):189-90. doi: 10.1038/bjc.1988.190.
3
Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.新型抗叶酸剂N10-炔丙基-5,8-二氮杂叶酸（CB3717）治疗恶性间皮瘤的II期研究
Cancer Treat Rep. 1986 Nov;70(11):1335-6.
4
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.
Eur J Cancer Clin Oncol. 1988 Apr;24(4):733-6. doi: 10.1016/0277-5379(88)90307-0.
5
A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.
Eur J Cancer Clin Oncol. 1988 Feb;24(2):201-4. doi: 10.1016/0277-5379(88)90253-2.
6
Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.
Eur J Cancer Clin Oncol. 1988 Apr;24(4):769-75. doi: 10.1016/0277-5379(88)90313-6.
7
8
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.喹唑啉抗叶酸胸苷酸合成酶抑制剂N10-炔丙基-5,8-二去氮叶酸（CB3717）的I期评估。
J Clin Oncol. 1986 Aug;4(8):1245-52. doi: 10.1200/JCO.1986.4.8.1245.
9
10
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.N10-炔丙基-5,8-二氮杂叶酸（CB3717）和一种非肾毒性类似物ICI D1694对小鼠的肾脏影响。
Br J Cancer. 1991 Nov;64(5):833-8. doi: 10.1038/bjc.1991.409.
引用本文的文献
1
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.从甲氨蝶呤到培美曲塞及其他。抗叶酸药物的药效学和临床特性综述。
Invest New Drugs. 2006 Jan;24(1):37-77. doi: 10.1007/s10637-005-4541-1.
2
Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.拓姆替克（ZD1694）：从概念到医疗，合理药物研发项目
Invest New Drugs. 1996;14(3):305-16. doi: 10.1007/BF00194534.
3
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.胸苷酸合成酶的叶酸类抑制剂对MGH-U1细胞的生化作用。
Cancer Chemother Pharmacol. 1994;35(2):109-14. doi: 10.1007/BF00686631.
4
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).CB3717（N10-炔丙基-5,8-二去氮叶酸）抑制胸苷酸合成酶并不能增强5-氟尿嘧啶对人类结直肠癌的疗效。
Br J Cancer. 1988 Aug;58(2):189-90. doi: 10.1038/bjc.1988.190.
5
Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.5-氟尿嘧啶联合疗法对人结肠癌细胞RNA加工的影响。
Br J Cancer. 1990 Mar;61(3):415-9. doi: 10.1038/bjc.1990.91.
本文引用的文献
1
Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
Cancer Res. 1981 Mar;41(3):994-9.
2
A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.一种强效的胸苷酸合成酶喹唑啉类抗肿瘤抑制剂：合成、生物学特性及对小鼠的治疗效果
Eur J Cancer (1965). 1981 Jan;17(1):11-9. doi: 10.1016/0014-2964(81)90206-1.
3
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.喹唑啉抗叶酸胸苷酸合成酶抑制剂N10-炔丙基-5,8-二去氮叶酸（CB3717）的I期评估。
J Clin Oncol. 1986 Aug;4(8):1245-52. doi: 10.1200/JCO.1986.4.8.1245.
4
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.一项关于近期在结直肠癌中对5-氟尿嘧啶治疗进行生化调节或增强的方法的对照评估。
J Clin Oncol. 1985 Dec;3(12):1624-31. doi: 10.1200/JCO.1985.3.12.1624.
Zotero 插件